Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2). (2020). SKIN The Journal of Cutaneous Medicine, 4(6), s96. https://doi.org/10.25251/skin.4.supp.96